1. Home
  2. DTF vs SPRO Comparison

DTF vs SPRO Comparison

Compare DTF & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DTF Tax-Free Income 2028 Term Fund Inc.

DTF

DTF Tax-Free Income 2028 Term Fund Inc.

SELL

Current Price

$11.30

Market Cap

80.5M

Sector

Finance

ML Signal

SELL

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTF
SPRO
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.5M
67.0M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
DTF
SPRO
Price
$11.30
$1.07
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
10.1K
★ 461.5K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 111.81
EPS
★ N/A
N/A
Revenue
N/A
★ $66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 39.24
52 Week Low
$11.14
$1.08
52 Week High
$11.61
$3.08

Technical Indicators

Market Signals
Indicator
DTF
SPRO
Relative Strength Index (RSI) 48.16 39.23
Support Level $11.14 N/A
Resistance Level $11.56 $1.28
Average True Range (ATR) 0.10 0.06
MACD 0.01 -0.01
Stochastic Oscillator 36.11 0.00

Price Performance

Historical Comparison
DTF
SPRO

About DTF DTF Tax-Free Income 2028 Term Fund Inc.

DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: